Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors. These novel therapies are FVIII mimetics, antithro...

Descripción completa

Detalles Bibliográficos
Autor principal: Mahlangu, Johnny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131856/
https://www.ncbi.nlm.nih.gov/pubmed/34026796
http://dx.doi.org/10.3389/fmed.2021.670526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131856/
https://www.ncbi.nlm.nih.gov/pubmed/34026796
http://dx.doi.org/10.3389/fmed.2021.670526

Ejemplares similares